The binding of peroxidase-labelled lectins to human endometrium in normal cyclical endometrium and endometrial adenocarcinoma

K P WEST, JANET L COPE

From the Department of Pathology, Clinical Sciences Building, Leicester Royal Infirmary, Leicester

SUMMARY The nature of endometrial glycoconjugates throughout the menstrual cycle was investigated using a panel of lectins directed against specific sugar groups. This approach was also applied to a series of endometrial adenocarcinomas the findings for which were compared with those of normal controls. A change in the expression of glycosubstances was found in relation to the phase of the menstrual cycle; that there was increasing sialylation of terminal galactose groups during the secretory phase. This change may be influenced by progesterone. One group of endometrial adenocarcinomas exhibited binding patterns similar to those seen in secretory endometrium and this may be related to progesterone receptor state. Expression of fucose containing glycosubstances was identified in half of the carcinomas but not in the normal control tissue, thus indicating that a change in fucosylation occurs with endometrial neoplasia. None of the lectin binding patterns, however, correlated with variables in the patients themselves or within the tumours.

Lectins are proteins and glycoproteins derived from a wide variety of biological sources. Their various properties depend on their ability to bind specifically to certain saccharide residues. They are thus able to react with the glycosylated components of cells and have been extensively used in the study of both normal and neoplastic tissues including breast and large intestine. Studies of lectin binding in human endometrium have, however, been rather limited.

Various metabolic changes occur in the endometrium during the normal menstrual cycle, and changes in the activities of enzymes such as nonspecific esterases, lactate dehydrogenase, and alkaline phosphatase have been recorded. Glycogen is synthesised at certain stages of the cycle and changes in glycoprotein production also occur. Standard techniques of carbohydrate histochemistry such as periodic acid Schiff (PAS) and alcian blue have been applied to human endometrium. The use of lectins, however, permits more specific identification of changes in tissue carbohydrates which occur during the menstrual cycle.

The glycosylated components of cells and particularly of cell membranes have been implicated in several cellular reactions such as cell-cell interaction, cell-substrate interaction, and hormone binding. Changes in such properties could be important in the development of neoplasia and several studies have been performed comparing the glycosubstances of neoplastic cells with their normal counterparts. Lectins—for example, peanut and wheat germ agglutinins—have been previously used to detect changes in the carbohydrate composition of malignant cells both in tissue sections and in cell suspensions.

Only one previous study of lectin binding to human endometrial carcinoma, however, has been undertaken. The purpose of this study was to determine the pattern of lectin binding in endometrium during different phases of the menstrual cycle, to assess the reactivity of endometrial carcinomas, and to compare these to those of non-malignant tissues. The seven lectins used have a range of specificities encompassing galactose and N-acetyl-D-galactosamine, D-acetyl-D-glucosamine, sialic acid, fucose and mannose.

Material and methods

Fifty cases each of proliferative endometrium, secretory endometrium, and endometrial adenocarcinoma were retrieved from the histopathology files of this hospital. All specimens had been fixed in 10% formalin. The cases were divided into three groups. A, proliferative endometrium from women aged 18-50 with no clinical signs of neoplasm; B, secretory endometrium from women aged 18-50 with no clinical signs of neoplasm; C, endometrial adenocarcinoma from women aged 20-70.
unbuffered formol-saline and routinely processed to paraffin wax. In the cases of carcinoma the ages of the patients and their ABO blood group state were also recorded. Details of ABO blood groups were not available for the proliferative and secretory endometrium groups.

Sections stained with haematoxylin and eosin were examined to confirm the stage of the menstrual cycle using established criteria and the endometrial adenocarcinomas were graded into well, moderately, and poorly differentiated.

Horseradish peroxidase (HRP) conjugated lectins were obtained from Sigma Ltd (Poole, Dorset, England) and E-Y Laboratories (San Mateo, California, USA). After initial evaluation of concentrations ranging from 5–50 μg/ml a standard optimum concentration of 10 μg/ml was used for all lectins.

The staining procedure was as follows:

1. Deparaffinise 4 μm sections.
2. Block endogenous peroxidase activity for 30 minutes in 0-5% H₂O₂ in absolute methanol.
3. Wash in phosphate buffered saline (PBS).
4. Incubate with HRP lectin conjugate for 60 minutes at room temperature.
5. Wash in PBS.
6. Develop reaction product by incubation in 0.015% H₂O₂ and 0.05% diaminobenzidine tetrahydrochloride in PBS for five minutes.
7. Counterstain with haematoxylin.

The binding of all lectins was assessed both with and without pretreatment with 0-1% trypsin (Difco) with 0-1% calcium chloride in distilled water for 30 minutes at 37°C as enzyme digestion has been found to enhance the binding of lectins to paraffin wax sections in some instances. Similarly, the effect of neuraminidase on the binding of all the lectins was assessed by treatment of sections overnight with Vibrio cholerae neuraminidase (Koch-Light), 250 μg/ml in 0-1 M sodium acetate buffer, pH 5-5, containing 0-005 M calcium chloride. Controls were performed by omission of the HRP lectin conjugate and by incubation of the conjugates with appropriate and inappropriate inhibitory sugars at a concentration of 0-2 M.

The lectins used, together with their simple sugar specificities and the inhibitory sugars used as controls are shown in table 1.

### Results

Previous digestion of tissue sections with trypsin, while slightly enhancing the intensity of staining in a small number of cases, had no effect on the distribution of reactivity with any of the lectins used. Staining with all the lectins except *Lens culinaris* (LCA) was inhibited by incubation with the appropriate inhibitory sugars as shown in table 1. As LCA did not stain any of the cases studied the effect of its inhibitor could not be assessed. The binding of *Triticum vulgare* (WGA), *Ulex europaeus* (UEA), *Dolichos biflorus* (DBA) and LCA was unaffected by pretreatment with neuraminidase.
Fig 2a  Secretory endometrium stained with HRP-PNA without neuraminidase incubation. No positive staining is evident.

Fig 2b  Secretory endometrium stained with HRP-PNA following incubation with neuraminidase. There is strong luminal surface staining of endometrial glands.

Fig 3  Secretory endometrium stained with HRP-BSA following incubation with neuraminidase. Luminal surface staining of endometrial glands is evident.

Fig 4  Endometrial adenocarcinoma stained with HRP-PNA without neuraminidase. There is strong staining of surfaces of neoplastic glands.
Endometrial lectin binding

Table 2  Summary of results of lectin binding to cyclical endometrium

<table>
<thead>
<tr>
<th>Lectin</th>
<th>Proliferative (n = 50)</th>
<th>Early secretory (n = 22)</th>
<th>Mid-secretory (n = 18)</th>
<th>Late secretory (n = 10)</th>
</tr>
</thead>
<tbody>
<tr>
<td>WGA</td>
<td>50/50 Luminal surface and cytoplasmic staining in all glands</td>
<td>22/22 Luminal surface and cytoplasmic staining in all glands</td>
<td>18/18 Luminal surface and cytoplasmic staining in all glands</td>
<td>10/10 Luminal surface and cytoplasmic staining in all cases</td>
</tr>
<tr>
<td>After neuraminidase</td>
<td>50/50 No change</td>
<td>22/22 No change</td>
<td>18/18 No change</td>
<td>10/10 No change</td>
</tr>
<tr>
<td>PNA</td>
<td>50/50 Luminal surface staining (fig 1)</td>
<td>22/22 Luminal surface staining</td>
<td>18/18 Patchy luminal surface staining</td>
<td>10/10 Negative</td>
</tr>
<tr>
<td>After neuraminidase</td>
<td>50/50 No change</td>
<td>22/22 No change</td>
<td>18/18 Luminal surface staining</td>
<td>10/10 Luminal surface staining (fig 2)</td>
</tr>
<tr>
<td>DBA</td>
<td>50/50 Negative</td>
<td>12/22 Negative</td>
<td>10/18 Negative</td>
<td>5/10 Negative</td>
</tr>
<tr>
<td></td>
<td>Diffuse epithelial cytoplasmic staining</td>
<td>Variable luminal surface staining</td>
<td>Variable luminal surface staining</td>
<td>Variable luminal surface staining</td>
</tr>
<tr>
<td></td>
<td>47/50 Negative</td>
<td>Supranuclear and apical cytoplasmic staining</td>
<td>Supranuclear and apical cytoplasmic staining</td>
<td>Supranuclear and apical cytoplasmic staining</td>
</tr>
<tr>
<td>After neuraminidase</td>
<td>50/50 No change</td>
<td>22/22 No change</td>
<td>18/18 No change</td>
<td>10/10 No change</td>
</tr>
<tr>
<td>MPA</td>
<td>50/50 Supranuclear cytoplasmic staining</td>
<td>22/22 Supranuclear and apical cytoplasmic staining</td>
<td>18/18 Supranuclear and apical cytoplasmic staining</td>
<td>10/10 Suprancement and apical cytoplasmic staining</td>
</tr>
<tr>
<td>After neuraminidase</td>
<td>50/50 No change</td>
<td>22/22 No change</td>
<td>18/18 No change</td>
<td>10/10 Suprancement and apical cytoplasmic staining</td>
</tr>
<tr>
<td>BSA-1</td>
<td>50/50 Negative</td>
<td>22/22 Negative</td>
<td>18/18 Negative</td>
<td>10/10 Negative</td>
</tr>
<tr>
<td>After neuraminidase</td>
<td>50/50 No change</td>
<td>22/22 No change</td>
<td>18/18 No change</td>
<td>10/10 No change</td>
</tr>
<tr>
<td>UEA-1</td>
<td>45/50 Negative</td>
<td>22/22 Negative</td>
<td>18/18 Negative</td>
<td>10/10 No change</td>
</tr>
<tr>
<td></td>
<td>5/50 focal luminal surface staining</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>After neuraminidase</td>
<td>50/50 No change</td>
<td>22/22 No change</td>
<td>18/18 No change</td>
<td>10/10 No change</td>
</tr>
<tr>
<td>LCA</td>
<td>50/50 Negative</td>
<td>22/22 Negative</td>
<td>18/18 Negative</td>
<td>10/10 No change</td>
</tr>
<tr>
<td>After neuraminidase</td>
<td>50/50 No change</td>
<td>22/22 No change</td>
<td>18/18 No change</td>
<td>10/10 No change</td>
</tr>
</tbody>
</table>

Cyclical Endometrium

The cases of secretory endometrium were classified as early secretory (n = 22), mid-secretory (n = 18), and late secretory (n = 10). Consistent patterns of binding were observed with WGA, PNA, *Maclura pomifera* (MPA), *Bandideiraea simplicifolia* (BSA-1) and UEA-1 with differences being noted between proliferative and secretory endometrium for PNA and to a lesser extent DBA. The results are summarised in table 2.

Carcinomas

The endometrial adenocarcinomas were categorised as well differentiated (n = 34), moderately differentiated (n = 10), and poorly differentiated (n = 6). No correlation between the degree of differentiation and lectin binding, however, was observed. Furthermore, there was no association between lectin binding and age or ABO blood group. The results of the lectin binding studies are summarised in table 3.

PNA staining of tumour cell cytoplasm and luminal surfaces was observed in all carcinomas. Three groups of tumours could be identified. Ten cases showed scanty staining with less than 10% of the tumour reacting; 31 cases showed moderate staining with about 50% of the tumour being reactive; and nine cases showed abundant staining with more than 90% of the tumour reacting. Prior treatment with
neuraminidase resulted in staining throughout all tumours.

Discussion

By using a range of lectins of different and related specificities, variations were detected between different phases of the menstrual cycle and between malignant and non-malignant endometrium. Although consistent patterns of binding have been noted for proliferative and secretory endometrium with most of the lectins, an interesting change in the sialylation of certain terminal galactosyl groups between the two phases was observed. Changes in sialylation and fucosylation were also shown in carcinomas.

Interpretation of the results of lectin binding studies requires great caution. Firstly, it should be emphasised that the results of this study apply only to endometrial tissue fixed in formalin and processed to paraffin wax; the use of other means of fixation may produce different results. The effects of various fixatives on lectin binding have been studied in breast, skin, and oral mucosa. Furthermore, the binding of lectins is not as straightforward as simple inhibition experiments suggest, a point which must not be overlooked in considering the meaning of the results of lectin histochemistry. The use of specific glycosidases offers an alternative, but expensive means of control in lectin binding studies.

Table 3  Summary of results of lectin binding to endometrial adenocarcinomas

<table>
<thead>
<tr>
<th>Lectin</th>
<th>Well-differentiated (n = 34)</th>
<th>Moderately differentiated (n = 10)</th>
<th>Poorly differentiated (n = 6)</th>
</tr>
</thead>
<tbody>
<tr>
<td>WGA</td>
<td>34/34 Widespread luminal surface staining</td>
<td>10/10 Widespread luminal surface staining</td>
<td>6/6 Widespread luminal surface staining</td>
</tr>
<tr>
<td></td>
<td>Variable cytoplasmic staining</td>
<td>Variable cytoplasmic staining</td>
<td>Variable cytoplasmic staining</td>
</tr>
<tr>
<td>After neuraminidase</td>
<td>34/34 No change</td>
<td>10/10 No change</td>
<td>6/6 No change</td>
</tr>
<tr>
<td>PNA</td>
<td>6/34 Scanty staining (&lt; 10%) (fig 4)</td>
<td>2/10 Scanty staining</td>
<td>2/6 Scanty staining</td>
</tr>
<tr>
<td></td>
<td>22/34 Moderate staining (50%)</td>
<td>6/10 Moderate staining</td>
<td>2/6 Moderate staining</td>
</tr>
<tr>
<td></td>
<td>6/34 Abundant staining (&gt; 90%)</td>
<td>2/10 Abundant staining</td>
<td>2/6 Abundant staining</td>
</tr>
<tr>
<td>After neuraminidase</td>
<td>34/34 Abundant staining</td>
<td>10/10 Abundant staining</td>
<td>6/6 Abundant staining</td>
</tr>
<tr>
<td>DBA</td>
<td>18/34 Negative</td>
<td>4/10 Negative</td>
<td>3/6 Negative</td>
</tr>
<tr>
<td></td>
<td>10/34 Cytoplasmic staining alone</td>
<td>4/10 Cytoplasmic staining only</td>
<td>2/6 Cytoplasmic staining alone</td>
</tr>
<tr>
<td>After neuraminidase</td>
<td>6/34 Cytoplasmic and luminal surface staining</td>
<td>2/10 Cytoplasmic and luminal surface staining</td>
<td>1/6 Cytoplasmic and luminal surface staining</td>
</tr>
<tr>
<td>MPA</td>
<td>34/34 No change</td>
<td>10/10 No change</td>
<td>6/6 No change</td>
</tr>
<tr>
<td></td>
<td>10/34 Cytoplasmic staining</td>
<td>1/10 Negative</td>
<td>2/6 Cytoplasmic staining</td>
</tr>
<tr>
<td></td>
<td>9/34 Luminal surface staining</td>
<td>3/10 Cytoplasmic staining</td>
<td>1/6 Luminal surface staining</td>
</tr>
<tr>
<td></td>
<td>15/34 Cytoplasmic and luminal surface staining</td>
<td>4/10 Luminal surface staining</td>
<td>3/6 Cytoplasmic and luminal surface staining</td>
</tr>
<tr>
<td>After neuraminidase</td>
<td>34/34 Luminal surface staining</td>
<td>2/10 Cytoplasmic and luminal surface staining</td>
<td>2/6 Cytoplasmic and luminal surface staining</td>
</tr>
<tr>
<td></td>
<td>Cytoplasmic staining unchanged</td>
<td>6/6 Luminal surface staining</td>
<td>6/6 Luminal surface staining</td>
</tr>
<tr>
<td>BSA-1</td>
<td>27/34 Negative</td>
<td>7/10 Negative</td>
<td>3/6 Negative</td>
</tr>
<tr>
<td></td>
<td>7/34 Luminal surface staining</td>
<td>3/10 Luminal surface staining</td>
<td>3/6 Luminal surface staining</td>
</tr>
<tr>
<td>After neuraminidase</td>
<td>Negative cases unchanged</td>
<td>Negative cases unchanged</td>
<td>Negative cases unchanged</td>
</tr>
<tr>
<td></td>
<td>Increased surface staining in positive cases</td>
<td>Increased surface staining in positive cases</td>
<td>Increased surface staining in positive cases</td>
</tr>
<tr>
<td>UEA-1</td>
<td>15/34 Negative</td>
<td>4/10 Negative</td>
<td>3/6 Negative</td>
</tr>
<tr>
<td></td>
<td>19/34 Luminal surface staining (fig 5)</td>
<td>6/10 Luminal surface staining</td>
<td>3/6 Luminal surface staining</td>
</tr>
<tr>
<td>After neuraminidase</td>
<td>34/34 No change</td>
<td>10/10 No change</td>
<td>6/6 No change</td>
</tr>
<tr>
<td>LCA</td>
<td>34/34 Negative</td>
<td>10/10 Negative</td>
<td>6/6 Negative</td>
</tr>
<tr>
<td>After neuraminidase</td>
<td>34/34 No change</td>
<td>10/10 No change</td>
<td>6/6 No change</td>
</tr>
</tbody>
</table>

CYCLICAL ENDOMETRIUM

The results allow certain observations to be made about the nature of endometrial glycosubstances during the normal menstrual cycle. WGA binding sites were identified in the cytoplasm and at the luminal surfaces of epithelial cells throughout the menstrual cycle. WGA identifies N-acetyl-D-glucosamine, especially in dimeric or trimeric form but will also bind to sialic (N-acetylmuraminic) acid. As neuraminidase preferentially cleaves terminal sialic acid residues and it did not affect WGA binding, the lectin may be detecting N-acetyl-D-glucosamine in the endometrium. This cannot be stated with certainty, however, as we have no definitive proof that sialic acid is removed.

Despite apparent similarities lectins with affinity for D-galactosyl and N-acetyl-D-galactosaminyl residues produce varying results. PNA has a strong affinity for galactosyl-β-(1-3)-N-acetyl-D-galactosaminyl residues. The staining of the luminal surfaces of...
proliferative glands suggests that this disaccharide is present. The loss of reactivity in the secretory phase and its restoration by neuraminidase treatment indicates that sialylation of the PNA binding sites has occurred. An increase in sialomucins in late secretory endometrium has previously been shown histochemically.\textsuperscript{36} This could be the result of increased sialyl transferase activity, and the timing of this change suggests a possible role for progesterone in its mediation. Serum progesterone activities rise during the secretory phase and there is an increase in endometrial progesterone receptors at this time.\textsuperscript{37}

The binding of DBA also showed cyclical variations, although these were less pronounced than those seen with PNA. Terminal N-acetyl-D-galactosamine\textsuperscript{37} was detected at the luminal surface only in secretory endometrium. The distribution of this residue may, therefore, be controlled by a glycosyltransferase under hormonal influence.

MPA and BSA-1 showed consistent binding patterns throughout the menstrual cycle. MPA has affinity for $\alpha$-D-galactose and N-acetyl-D-galactosamine\textsuperscript{28-29} but will also bind to galactose-$\beta$-(1-3)-N-acetyl-D-galactosamine as does PNA.\textsuperscript{30} MPA binding sites were demonstrable in the endometrial epithelial cytoplasm and sialylated binding sites were present at the luminal surfaces. The cytoplasmic binding sites may represent nascent glycoproteins which then undergo sialylation before being transported to the luminal surface.

BSA-1 detected $\alpha$-D-galactosyl residues\textsuperscript{31} at the luminal surface of endometrial glands only after treatment with neuraminidase. Thus staining of endometrium with PNA and BSA-1 after such treatment identifies two oligosaccharides. One of these has a terminal $\alpha$-D-galactose residue as detected by BSA-1: this is present throughout the cycle and could also be detected by MPA. The other has a terminal galactose-$\beta$-(1-3)-N-acetyl-D-galactosamine detectable by PNA and is present in its complete form only in the secretory phase of the cycle.

With few exceptions, UEA-1 did not stain cyclical endometrium. This does not necessarily imply an absence of terminal L-fucose residues, however. UEA-1 has a predilection for the blood group H(O) oligosaccharide-fucose-$(1-2)$-$\beta$-D-galactosyl-$(1-4)$-N-acetyl D-glucosamine-$(1-6)$-P.\textsuperscript{33} L-fucose, therefore, may be present in human endometrium in a form undetectable by UEA-1. Details of blood groups were not available for the cyclical endometrium group. The results of Kluskens \textit{et al} for staining of proliferative endometrium with UEA-1 are similar to those of the present study.\textsuperscript{4}
gation UEA-1 also failed to stain endometrial carcinomas. Such a finding is not wholly inconsistent with our results as only 15 cases of carcinoma were examined.

Lack of staining of cyclical endometrium and endometrial carcinomas by LCA indicates the absence of detectable bi-antennate and tri-antennate N-linked glycans containing mannosyl residues. More than one commercial batch of the lectin was used, and other tissues comprising part of a different project were reactive. It therefore seems that the lack of staining by LCA in endometrial tissues was due to a lack of binding sites and not to any technical problems.

The results of this study show that HRP conjugated lectins can be used to show the presence of glycosylated components of both normal and neoplastic human endometrium in formalin fixed, paraffin wax processed tissues. Changes in these components can be detected at certain stages of the menstrual cycle and in neoplasia. Comparisons of binding patterns in normal proliferative and secretory endometrium with endometrial carcinomas, however, should be made with care as, by definition, the former come from premenopausal women and many of the latter are from postmenopausal women.

One avenue not explored in this study is the possible clinical importance of the extent and distribution of lectin staining in endometrial carcinomas in relation to tumour behaviour and prognosis. This could form the basis for a further study, as could a detailed study of lectin binding in atypical endometrial hyperplasia.

We thank Dr Rosemary Walker for helpful criticism in the preparation of the manuscript and Mrs Beverley Richardson, Mrs Wendy Pitts, and Mrs Margaret Hornby for their secretarial support.

References

16 Hakomori S. Structure and organization of cell surface glycolipid dependency on cell growth and malignant transformation. Biochim Biophys Acta 1975;419:55–89.
31 Murphy LA, Goldstein JJ. Five-D-galacto-pyranosyl binding
Endometrial lectin binding


Requests for reprints to: Dr K P West, Department of Pathology, Clinical Sciences Building, Leicester Royal Infirmary, PO Box 65, Leicester LE6 7LX, England.
The binding of peroxidase-labelled lectins to human endometrium in normal cyclical endometrium and endometrial adenocarcinoma.
K P West and J L Cope

*J Clin Pathol* 1989 42: 140-147
doi: 10.1136/jcp.42.2.140

Updated information and services can be found at:
http://jcp.bmj.com/content/42/2/140

These include:

**Email alerting service**
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Notes**

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/